Beth Rasmussen Email & Phone Number

• Led over 30 multi-disciplinary teams composed of discovery biology, medicinal chemistry, scale-up synthetic chemistry, drug metabolism, drug safety, pharmaceutical sciences, analytical chemistry, commercial and.
• Facilitated interactions and information exchange with multiple governance bodies and therapeutic area research councils.
• … Show more Led over 30 multi-disciplinary teams composed of discovery biology, medicinal chemistry, scale-up synthetic chemistry, drug metabolism, drug safety, pharmaceutical sciences, analytical chemistry, commercial.
• Established and maintained project management timeline data base for over 60 pre-development programs.
• Led 2 due diligence initiatives and facilitated interactions and data exchange between discovery and alliance partners on 3 programs in neuroscience and oncology.
• Wrote and annually updated the “Best Practices Guide” for Small Molecule Development, Late Discovery to pre-IND.

• Infectious Disease Research Leader, managed a group of 2 PhD senior scientists and 3 research associates in screen development, identification and evaluation of novel small molecule inhibitors of bacterial cell wall.
• Directed development and implementation of a high throughput screen designed to identify inhibitors of multiple steps in bacterial cell wall synthesis.
• Developed a yeast two-hybrid screen designed to identify small molecule inhibitors of bacterial cell… Show more Infectious Disease Research Leader, managed a group of 2 PhD senior scientists and 3 research associates.
• Developed a yeast two-hybrid screen designed to identify small molecule inhibitors of bacterial cell division.
• Liaised information exchange, management, and decision making related to the alliance between Wyeth and Millennium Pharmaceuticals. The alliance was established to identify novel antibacterial targets, perform targeted.

• Elucidated mechanisms of beta-lactam and tetracycline resistance. Cloned, expressed and evaluated many bacterial beta-lactamase enzymes representing classes A, B, C, and D, from species including Escherichia coli.
• Cloned, expressed, purified and characterized multiple unique bacterial beta-lactamases representing classes A, B, C, and D, from gram-negative bacteria including Escherichia and Aeromonas species as well as from the.
• Cloned, expressed, purified and characterized multiple unique bacterial beta-lactamases representing classes A, B, C, and D, from gram-negative bacteria including Escherichia and Aeromonas species as well as from the.
• Characterized the activity of novel glycylcycline antibacterial agents. One was fully developed and is a marketed as Tygacil, a $200M/year product.
• Discovered that the DsbAB system (responsible for protein disulfide formation in Escherichia coli) plays a major role in the phenotypic lack of expression of the Bacteriodes fragilis metallo-beta-lactamase, CcrA, in E..
• Identified the first “two-component” regulatory system that regulates expression of three different beta-lactamases in Aeromonas jandaei.

Phd, Microbiology And Immunology

Advisor: Philip J. Bassford, Jr., Dissertation: “Protein Localization in Escherichia coli”

Bs, Microbiology And Public Health

Activities and Societies: Member of Tower Guard

Visiting Research Fellow, Bacterial Genetics

Mentor: Thomas J. Silhavy, Research focus: “Localization of the Escherichia coli membrane protein, LamB”